Mesoblast Receives RMAT For LVAD Heart Failure Patients
Filed with ASX · · 3 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallEarlier from Mesoblast
- Mesoblasts P3 GVHD Trial Completes Enrollment
- Mesoblast Grants TiGenix License For Treatment of Fistulae
- MSB Named Global Technology Leader In Cell Therapy Industry
- Response to ASX Aware Letter Query
- Mesoblast Provides Corporate Update and Q1 Financial Results
Later from Mesoblast
- Appendix 3B with prospectus
- Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial
- GVHD Day 28 Results Presentation
- MSB Enters Into $75 Million Non-Dilutive Credit Facility
- Partnership For Allogeneic Cell-based Cancer Immunotherapies
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast